{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:35:56Z","timestamp":1791192956868,"version":"4.1.0"},"reference-count":43,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2015,6,16]],"date-time":"2015-06-16T00:00:00Z","timestamp":1434412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therap Adv Gastroenterol"],"published-print":{"date-parts":[[2015,9]]},"abstract":"<jats:p> Chronic hepatitis C (CHC) affects over 185 million individuals worldwide, approximately 3% of the world\u2019s population. CHC can lead to quality of life impairment, cirrhosis, hepatocellular carcinoma (HCC), liver failure and liver-related death. While CHC has been associated with increases in HCC, liver-related mortality and all-cause mortality, being cured of CHC is associated with improvement in these outcomes. Older interferon-based regimens were complex and toxic and required 6\u201312 months of therapy, with cure rates averaging around 40\u201345% for HCV genotype 1. Newer interferon-free regimens are now available in the US, Europe, Japan and in other countries. These regimens have short durations, minimal side effects, low pill burden and efficacy approaching 90\u2013100%. We may eventually see single-tablet regimens lasting no more than 4\u20136 weeks. This review will summarize the data regarding these interferon-free regimens, including Gilead\u2019s Harvoni (sofosbuvir\/ledipasvir), AbbVie\u2019s Viekira Pak (paritaprevir\/ritonavir\/ombitasvir with dasabuvir), and Janssen\u2019s Olysio (simeprevir) with sofosbuvir. Some practical considerations as we move into an interferon-free era will also be discussed, such as patient adherence and drug\u2013drug interactions. <\/jats:p>","DOI":"10.1177\/1756283x15587481","type":"journal-article","created":{"date-parts":[[2015,6,18]],"date-time":"2015-06-18T00:00:22Z","timestamp":1434585622000},"page":"298-312","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":85,"title":["The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment"],"prefix":"10.1177","volume":"8","author":[{"given":"Brian P.","family":"Lam","sequence":"first","affiliation":[{"name":"Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Jeffers","sequence":"additional","affiliation":[{"name":"Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Younoszai","sequence":"additional","affiliation":[{"name":"Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousef","family":"Fazel","sequence":"additional","affiliation":[{"name":"Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zobair M.","family":"Younossi","sequence":"additional","affiliation":[{"name":"Betty and Guy Beatty Center for Integrated Research, Claude Moore Health Education and Research Building, 3300 Gallows Road, Falls Church, VA 22042, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2015,6,16]]},"reference":[{"key":"bibr1-1756283X15587481","unstructured":"AbbVie Inc. (2015a) Viekira Pak (prescribing information). North Chicago, Illinois: AbbVie Inc."},{"key":"bibr2-1756283X15587481","unstructured":"AbbVie Ltd (2015b) Exviera (prescribing information). Maidenhead, UK: AbbVie Ltd."},{"key":"bibr3-1756283X15587481","unstructured":"AbbVie Ltd (2015c) Viekirax (prescribing information). Maidenhead, UK: AbbVie Ltd."},{"key":"bibr4-1756283X15587481","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316366"},{"key":"bibr5-1756283X15587481","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402454"},{"key":"bibr6-1756283X15587481","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.04.045"},{"key":"bibr7-1756283X15587481","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-10-200605160-00004"},{"key":"bibr8-1756283X15587481","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02494.x"},{"key":"bibr9-1756283X15587481","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.3.47"},{"key":"bibr10-1756283X15587481","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25606"},{"key":"bibr11-1756283X15587481","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.09.067"},{"key":"bibr12-1756283X15587481","volume":"60","author":"Dieterich D.","year":"2014","journal-title":"Hepatology"},{"key":"bibr13-1756283X15587481","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315722"},{"key":"bibr14-1756283X15587481","doi-asserted-by":"publisher","DOI":"10.1038\/nature04082"},{"key":"bibr15-1756283X15587481","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402338"},{"key":"bibr16-1756283X15587481","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.03.051"},{"key":"bibr17-1756283X15587481","volume":"60","author":"Jensen D.","year":"2014","journal-title":"Hepatology"},{"key":"bibr18-1756283X15587481","first-page":"14","volume-title":"Special Issue: Abstracts From the 2014 Conference on Retroviruses and Opportunistic Infections","volume":"22","author":"Kohli A.","year":"2014"},{"key":"bibr19-1756283X15587481","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402355"},{"key":"bibr20-1756283X15587481","doi-asserted-by":"publisher","DOI":"10.1586\/17512433.2014.928196"},{"key":"bibr21-1756283X15587481","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61036-9"},{"key":"bibr22-1756283X15587481","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.35950"},{"key":"bibr23-1756283X15587481","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(00)00026-X"},{"key":"bibr24-1756283X15587481","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2008.00973.x"},{"key":"bibr25-1756283X15587481","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27259"},{"key":"bibr26-1756283X15587481","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26141"},{"key":"bibr27-1756283X15587481","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2011.05.028"},{"key":"bibr28-1756283X15587481","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402869"},{"key":"bibr29-1756283X15587481","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2010.05.006"},{"key":"bibr30-1756283X15587481","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12350"},{"key":"bibr31-1756283X15587481","doi-asserted-by":"publisher","DOI":"10.1016\/S1665-2681(19)30840-3"},{"key":"bibr32-1756283X15587481","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-157-9-201211060-00529"},{"key":"bibr33-1756283X15587481","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu643"},{"key":"bibr34-1756283X15587481","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26978"},{"key":"bibr35-1756283X15587481","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27757"},{"key":"bibr36-1756283X15587481","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12625"},{"key":"bibr37-1756283X15587481","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.03.014"},{"key":"bibr38-1756283X15587481","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.11.032"},{"key":"bibr39-1756283X15587481","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27724"},{"key":"bibr40-1756283X15587481","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27161"},{"key":"bibr41-1756283X15587481","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv005"},{"key":"bibr42-1756283X15587481","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.04.003"},{"key":"bibr43-1756283X15587481","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1401561"}],"container-title":["Therapeutic Advances in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1756283X15587481","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1756283X15587481","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1756283X15587481","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T17:35:50Z","timestamp":1740764150000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1756283X15587481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,16]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["10.1177\/1756283X15587481"],"URL":"https:\/\/doi.org\/10.1177\/1756283x15587481","relation":{},"ISSN":["1756-2848","1756-2848"],"issn-type":[{"value":"1756-2848","type":"print"},{"value":"1756-2848","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,16]]}}}